← All peptidesPDA-V1 attestation Citations
verifiedBioGate · GREENGrade B
Dulaglutide (Trulicity)
HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGLong-acting GLP-1 receptor agonist fused to Fc; ~5-day half-life via FcRn recycling. Approved for T2D and MACE reduction.
GLP-1 analog fused to IgG4 Fc fragmentweekly SC dosing
MW
59670.00
Length
31aa
Posterior
39.1%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · GLP-1 analog fused to IgG4 Fc fragment
Cryptographic chain of custody.
- Outer PDA hash
- Inputs hash
- Merkle root
- TEE attestation
- Protocol version
- PDA-V1
- Source
- peptide-md
- Model version
- structure-fm-2026.04
- Candidates emitted
- 2
- Signed
- 2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with
@peptide-md/verifier.Real-world evidence
Cohort-attested outcomes.
Cohorts
4
Participants
237
Mean Δ
-1.71
Δ HRV ms (8-week) · 95% CI [-2.32, -1.09]
IPNFT · Molecule IPNFT V2Solana
Dulaglutide (Trulicity)
e70813…d9e208Royalty cascade
10.20%
Holders
450
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Source literature.
Grade A2014 · Diabetes Care
Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes (AWARD-3)
Umpierrez G et al.